PharmAbcine Decides on 3.7 Billion KRW Third-Party Allotment Capital Increase
Antibody drug developer PharmAbcine announced on the 17th that it has decided to conduct a third-party allotment paid-in capital increase to raise 3.7 billion KRW for operating funds and other purposes. New shares totaling 5,302,565 common shares will be issued at 700 KRW per share. The third-party allotment recipients include Kim Jeong-gyu (CEO, 1 million shares) and Kim Seong-yeon (a special relation of the CEO, 1 million shares), among others.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- "I Take Full Responsibility"... Seongjae Ahn Issues Direct Apology for 'Wine Swi...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
